COMP <GO>
TXG vs UNH // RETURN ON INVESTED CAPITAL (ROIC)
10x Genomics Inc. (NASDAQ) VS. UnitedHealth Group Incorporated (NYSE) • 15-METRIC TALLY: TXG 4
— UNH 9
▲ RETURN ON INVESTED CAPITAL (ROIC) LEADER: UNH
LAST: $61.63 (-12.09%) • MKT CAP: $8.03B
roic
-5.70%
LAST: $400.44 (-1.60%) • MKT CAP: $359.43B
roic
12.38%
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (TXG VS. UNH)
EMERALD CELL = QUANTITATIVE EDGE
| INSTITUTIONAL METRIC | TXG | UNH | SPREAD (A - B) | ADVANTAGE | DEDICATED URL |
|---|---|---|---|---|---|
| Gross Profit Margin | 69.10% | 88.31% | -19.21 | UNH | /gross-margins <GO> |
| Return on Invested Capital (ROIC) ACTIVE | -5.70% | 12.38% | -18.08 | UNH | /roic <GO> |
| EV/EBITDA & P/E Valuation | — | 15.3x | — | TIE | /valuation <GO> |
| Free Cash Flow Yield | 1.22% | 6.25% | -5.03 | UNH | /fcf-yield <GO> |
| Operating Margin | -9.50% | 5.32% | -14.82 | UNH | /operating-margins <GO> |
| Net Profit Margin | -6.80% | 3.53% | -10.33 | UNH | /net-margins <GO> |
| Revenue Growth (YoY) | 5.20% | 3.33% | +1.87 | TXG | /revenue-growth <GO> |
| Dividend Yield & FCF Payout Safety | 0.00% | 2.29% | -2.29 | UNH | /dividend-safety <GO> |
| Altman Z-Score & Debt/Equity | 25.02 | 3.09 | +21.93 | TXG | /balance-sheet <GO> |
| Piotroski F-Score Quality | 8/9 | 7/9 | +1.00 | TXG | /piotroski-score <GO> |
| Options Implied Move & Put/Call Skew | — | 7.00% | — | TIE | /options-implied-move <GO> |
| RSI-14 & 200D SMA Momentum | 39.5 | 55.1 | -15.60 | UNH | /rsi-technicals <GO> |
| 10Y Yield & FRED Macro Beta | 1.15 | 0.33 | +0.82 | TXG | /macro-sensitivity <GO> |
| Forward P/E Multiple | 24.0x | 17.7x | +6.26 | UNH | /forward-pe <GO> |
| Enterprise Scale & Market Cap | $8.03B | $359.43B | -$351.40B | UNH | /market-cap <GO> |
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
| FISCAL YEAR | TXG REV | UNH REV | TXG GROSS % | UNH GROSS % | TXG FCF | UNH FCF |
|---|---|---|---|---|---|---|
| FY 2025 | $642.8M | $447.57B | 69.1% | 88.7% | $130.1M | $16.07B |
| FY 2024 | $610.8M | $400.28B | 67.9% | 88.3% | -$5.7M | $20.70B |
| FY 2023 | $618.7M | $371.62B | — | 89.6% | -$43.0M | $25.68B |
| FY 2022 | — | $324.16B | — | 89.6% | — | $23.40B |
| FY 2021 | — | $287.60B | — | 89.2% | — | $19.89B |
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
TXG // BETA 1.15
UNH // BETA 0.33